RESUMEN
AIMS/HYPOTHESIS: A protective role of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP1-ra) in the development of diabetic retinopathy and diabetic macular oedema has been described in some recent studies, which may extend beyond glycaemic control. We aimed to review the clinical impact of SGLT2i and GLP1-ra therapy on the risk of diabetic retinopathy and diabetic macular oedema in individuals with type 2 diabetes taking insulin. METHODS: This is a retrospective cohort analysis of approximately two million people with type 2 diabetes receiving insulin across 97 healthcare organisations using a global federated health research network (TriNetX, Cambridge, USA). Two intervention cohorts (SGLT2i + insulin, n=176,409; GLP1-ra + insulin, n=207,034) were compared against a control cohort (insulin with no SGLT2i/GLP1-ra, n=1,922,312). Kaplan-Meier survival analysis was performed and estimated HRs were reported for each outcome. Propensity score was used to 1:1 match for age, sex, ischaemic heart disease, hypertension, microvascular complications, chronic kidney disease, HbA1c, BMI and use of pioglitazone, lipid modifying agents, antilipemic agents, ACE inhibitors, angiotensin II inhibitors and metformin. A sub-analysis comparing the two intervention cohorts was also performed. RESULTS: SGLT2i with insulin was associated with a reduced HR (95% CI) for diabetic macular oedema compared with the control cohort (0.835; 0.780, 0.893), while GLP1-ra with insulin demonstrated a lack of signal with no statistical significance to the HR (1.013; 0.960, 1.069). SGLT2i with insulin was not associated with a clinically significant increase in the risk of developing diabetic retinopathy (1.076; 1.027, 1.127), while GLP1-ra with insulin increased diabetic retinopathy risk (1.308; 1.261, 1.357). Compared with SGLT2i with insulin, GLP1-ra with insulin was associated with higher risk of diabetic retinopathy (1.205; 1.153, 1.259) and diabetic macular oedema (1.130; 1.056, 1.208). CONCLUSIONS/INTERPRETATION: Our study suggests that the combination of SGLT2i and insulin is associated with lower risk of developing diabetic macular oedema. However, the use of GLP1-ra was associated with an increased risk of diabetic retinopathy in individuals with type 2 diabetes also taking insulin. A comparative analysis showed favourable outcomes with SGLT2i and insulin in the development of diabetic macular oedema and diabetic retinopathy. RCTs using dedicated retinal imaging are required to determine the causal relationship with these therapies.
Asunto(s)
Diabetes Mellitus Tipo 2 , Retinopatía Diabética , Receptor del Péptido 1 Similar al Glucagón , Edema Macular , Inhibidores del Cotransportador de Sodio-Glucosa 2 , Humanos , Retinopatía Diabética/tratamiento farmacológico , Retinopatía Diabética/epidemiología , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/complicaciones , Inhibidores del Cotransportador de Sodio-Glucosa 2/uso terapéutico , Edema Macular/tratamiento farmacológico , Edema Macular/epidemiología , Masculino , Estudios Retrospectivos , Femenino , Persona de Mediana Edad , Anciano , Receptor del Péptido 1 Similar al Glucagón/agonistas , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéuticoRESUMEN
BACKGROUND: As the retina is suggested to mirror the brain, we hypothesized that diabetic retinopathy and macular edema are indicative of stroke risk in type 1 diabetes and sought to assess this association in individuals with type 1 diabetes. METHODS: We included 1,268 adult FinnDiane Study participants with type 1 diabetes (age 38.7 ± 11.8 years, 51.7% men vs. 48.3% women, and 31.5% had diabetic kidney disease), data on baseline diabetic retinopathy severity, and first stroke during our observational follow-up. Retinopathy was graded by the Early Treatment Diabetic Retinopathy Study (ETDRS) scale, and macular edema as clinically significant (CSME) or not. Strokes identified from registries were confirmed from medical files. Adjusted hazard ratios (HR) for stroke by retinopathy severity and CSME were calculated by Cox models adjusted for clinical confounders, including diabetic kidney disease. RESULTS: During median 18.0 (14.1-19.3) follow-up years, 130 strokes (96 ischemic, 34 hemorrhagic) occurred. With no-very mild (ETDRS 10-20) retinopathy as reference, the adjusted HR for stroke was 1.79 (95%CI 1.02-3.15) in non-proliferative (ETDRS 35-53), and 1.69 (1.02-2.82) in proliferative (ETDRS 61-85) retinopathy. Corresponding adjusted HR for ischemic stroke was 1.68 (0.91-3.10) in non-proliferative and 1.35 (0.77-2.36) in proliferative retinopathy. The adjusted HR for hemorrhagic stroke was 2.84 (0.66-12.28) in non-proliferative and 4.31 (1.16-16.10) in proliferative retinopathy. CSME did not increase HR for any stroke type after adjustment for clinical confounders (data not shown). CONCLUSIONS: Stroke incidence increases with the severity of diabetic retinopathy independently of comorbid conditions, including diabetic kidney disease.
Asunto(s)
Diabetes Mellitus Tipo 1 , Retinopatía Diabética , Edema Macular , Índice de Severidad de la Enfermedad , Humanos , Diabetes Mellitus Tipo 1/epidemiología , Diabetes Mellitus Tipo 1/diagnóstico , Diabetes Mellitus Tipo 1/complicaciones , Retinopatía Diabética/epidemiología , Retinopatía Diabética/diagnóstico , Femenino , Masculino , Edema Macular/epidemiología , Edema Macular/diagnóstico , Incidencia , Adulto , Persona de Mediana Edad , Factores de Riesgo , Factores de Tiempo , Finlandia/epidemiología , Medición de Riesgo , Sistema de Registros , Accidente Cerebrovascular Isquémico/epidemiología , Accidente Cerebrovascular Isquémico/diagnóstico , Accidente Cerebrovascular/epidemiología , Accidente Cerebrovascular/diagnóstico , Accidente Cerebrovascular Hemorrágico/epidemiología , Accidente Cerebrovascular Hemorrágico/diagnósticoRESUMEN
AIM: We assessed the effectiveness of sodium-glucose co-transporter 2 inhibitors (SGLT2is) in reducing the administration frequency of anti-vascular endothelial growth factor (VEGF) agents in patients with diabetic macular oedema (DMO) using a health insurance claims database. MATERIALS AND METHODS: This retrospective cohort study analysed health insurance claims data covering 11 million Japanese patients between 2005 and 2019. We analysed the frequency and duration of intravitreal injection of anti-VEGF agents after initiating SGLT2is or other antidiabetic drugs. RESULTS: Among 2412 matched patients with DMO, the incidence rates of anti-VEGF agent injections were 230.1 per 1000 person-year in SGLT2i users and 228.4 times per 1000 person-year in non-users, respectively, and the risk ratio for events was unchanged in both groups. Sub-analysis of each baseline characteristic of the patients showed that SGLT2is were particularly effective in patients with a history of anti-VEGF agent use [p = .027, hazard ratio (HR): 0.44, 95% confidence interval (CI): 0.22-0.91]. SGLT2is reduced the risk for the first (p = .023, HR: 0.45, 95% CI: 0.22-0.91) and second (p = .021, HR: 0.39, 95% CI: 0.17-0.89) anti-VEGF agent injections. CONCLUSIONS: There was no difference in the risk ratio for the addition of anti-VEGF therapy between the two treatment groups. However, the use of SGLT2is reduced the frequency of anti-VEGF agent administration in patients with DMO requiring anti-VEGF therapy. Therefore, SGLT2i therapy may be a novel, non-invasive, low-cost adjunctive therapy for DMO requiring anti-VEGF therapy.
Asunto(s)
Retinopatía Diabética , Edema Macular , Inhibidores del Cotransportador de Sodio-Glucosa 2 , Simportadores , Humanos , Edema Macular/tratamiento farmacológico , Edema Macular/epidemiología , Edema Macular/inducido químicamente , Ranibizumab/efectos adversos , Bevacizumab/efectos adversos , Inhibidores de la Angiogénesis/uso terapéutico , Inhibidores de la Angiogénesis/efectos adversos , Factores de Crecimiento Endotelial/uso terapéutico , Factor A de Crecimiento Endotelial Vascular/uso terapéutico , Estudios de Cohortes , Estudios Retrospectivos , Inhibidores del Cotransportador de Sodio-Glucosa 2/uso terapéutico , Japón/epidemiología , Retinopatía Diabética/complicaciones , Retinopatía Diabética/tratamiento farmacológico , Retinopatía Diabética/epidemiología , Simportadores/uso terapéutico , Glucosa/uso terapéutico , Sodio , Inyecciones IntravítreasRESUMEN
BACKGROUND: To determine the prevalence, clinical characteristics, and independent predictors of uveitic macular edema (UME) in patients with intermediate, posterior and panuveitis. METHODS: We retrospectively reviewed the records of patients with intermediate, posterior, and panuveitis who underwent macular assessment using optical coherence tomography between January 2015 and February 2020. The prevalence of UME and clinical characteristics of the patients were described. Predictors of UME were identified using multivariate regression analysis. RESULTS: A total of 349 patients were included. The mean age was 41 years, female: male ratio was 1.3:1. The prevalence of UME was 51.9%. UME was found in 33.9%, 56.9%, and 54.1% of the intermediate, posterior, and panuveitis cases, respectively. Among patients with UME, 47% had infectious uveitis, 32.6% had idiopathic uveitis, and 20.4% had immune-mediated uveitis. Diffuse macular edema was the most frequently observed pattern (36.5%). Multivariate analysis showed that factors independently associated with UME included age at uveitis onset (adjusted odds ratio [aOR] 1.01, 95% confidence interval [CI] 1.00-1.03, P = 0.036), PU and panuveitis compared with intermediate uveitis (aOR 2.09, 95% CI 1.14-3.86, P = 0.018), and infectious uveitis compared with noninfectious uveitis (aOR 2.13, 95% CI 1.34-3.37, P = 0.001). CONCLUSIONS: Increasing age at uveitis onset, posterior/panuveitis, and infectious etiology are predictive factors for UME in patients with intermediate, posterior and panuveitis.
Asunto(s)
Edema Macular , Tomografía de Coherencia Óptica , Uveítis , Humanos , Estudios Retrospectivos , Masculino , Femenino , Edema Macular/epidemiología , Edema Macular/diagnóstico , Adulto , Prevalencia , Tomografía de Coherencia Óptica/métodos , Persona de Mediana Edad , Uveítis/epidemiología , Uveítis/diagnóstico , Agudeza Visual , Factores de Riesgo , Adulto Joven , Singapur/epidemiologíaRESUMEN
SIGNIFICANCE: Suspected clinically significant macular edema (SCSME) from exudates differed among ethnic groups in our underserved population. African American and Asian subjects had higher prevalence than Hispanics and non-Hispanic Caucasians, from the same clinics. Men had higher prevalence than women. Highly elevated blood glucose was frequent and associated with SCSME. PURPOSE: We investigated the association between the presence of SCSME from exudates and hemoglobin A1c (HbA1c), as well as demographic factors such as age, sex, and ethnic group. Our population was underserved diabetic patients from the same geographic locations. Ethnic groups were White Hispanic, non-Hispanic Caucasian, African American, and Asian, with a high proportion of underrepresented minorities. METHODS: In a diabetic retinopathy screening study at four community clinics in Alameda County, California, nonmydriatic 45° color fundus images were collected from underserved diabetic subjects following the EyePACS imaging protocol. Images were analyzed for SCSME from exudates by two certified graders. Logistic regression assessed the association between SCSME from exudates and age, sex, ethnic group, and HbA1c. RESULTS: Of 1997 subjects, 147 (7.36%) had SCSME from exudates. The mean ± standard deviation age was 53.4 ± 10.5 years. The mean ± standard deviation HbA1c level was 8.26 ± 2.04. Logistic regression analysis indicated a significant association between presence of SCSME from exudates and HbA1c levels (p<0.001), sex (p=0.027), and ethnicity (p=0.030). African Americans (odds ratio [OR], 1.63; 95% confidence interval [CI], 1.06 to 2.50; p=0.025) and Asians (OR, 1.63; 95% CI, 1.05 to 2.54; p=0.029) had a higher risk than Hispanics. After adjusting for ethnicity, sex, and age, the odds of developing SCSME from exudates increased by 26.5% with every 1% increase in HbA1c level (OR, 1.26; 95% CI, 1.18 to 1.36; p<0.001). CONCLUSIONS: In our underserved population, many diabetic patients had very high HbA1c values. Ethnic background (African American > Asians > Hispanics), sex (male > female), and HbA1c level were strong indicators for identifying who is at increased risk of developing SCSME from exudates.
Asunto(s)
Diabetes Mellitus , Edema Macular , Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Hemoglobina Glucada , Edema Macular/diagnóstico , Edema Macular/epidemiología , Poblaciones Vulnerables , Demografía , Factores de RiesgoRESUMEN
BACKGROUND: Diabetic macular edema (DME) is the main cause of irreversible vision loss in patients with diabetes mellitus (DM), resulting in a certain burden to patients and society. With the increasing incidence of DME, more and more researchers are focusing on it. METHODS: The papers related to DME between 2012 and 2022 from the Web of Science core Collection were searched in this study. Based on CiteSpace and VOS viewer, these publications were analyzed in terms of spatiotemporal distribution, author distribution, subject classification, topic distribution, and citations. RESULTS: A total of 5165 publications on DME were included. The results showed that the research on DME is on a steady growth trend. The country with the highest number of published documents was the US. Wong Tien Yin from Tsinghua University was the author with the most published articles. The journal of Retina, the Journal of Retinal and Vitreous Diseases had a large number of publications. The article "Mechanisms of macular edema: Beyond the surface" was the highly cited literature and "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema" had the highest co-citation frequency. The treatment, diagnosis, pathogenesis, as well as etiology and epidemiological investigation of DME, have been the current research direction. Deep learning has been widely used in the medical field for its strong feature representation ability. CONCLUSIONS: The study revealed the important authoritative literature, journals, institutions, scholars, countries, research hotspots, and development trends in in the field of DME. This indicates that communication and cooperation between disciplines, universities, and countries are crucial. It can advance research in DME and even ophthalmology.
Asunto(s)
Retinopatía Diabética , Edema Macular , Humanos , Retinopatía Diabética/complicaciones , Edema Macular/epidemiología , Edema Macular/etiología , Ranibizumab , Bevacizumab , BibliometríaRESUMEN
BACKGROUND: Diabetic Macular Edema (DME) significantly impairs vision in diabetics, with varied patient responses to current treatments like anti-vascular endothelial growth factor (VEGF) therapy underscoring the necessity for continued research into more effective strategies. This study aims to evaluate global research trends and identify emerging frontiers in DME to guide future research and clinical management. METHODS: A qualitative and quantitative analysis of publications related to diabetic macular edema retrieved from the Web of Science Core Collection (WoSCC) between its inception and September 4, 2023, was conducted. Microsoft Excel, CiteSpace, VOSviewer, Bibliometrix Package, and Tableau were used for the bibliometric analysis and visualization. This encompasses an examination of the overall distribution of annual output, major countries, regions, institutions, authors, core journals, co-cited references, and keyword analyses. RESULTS: Overall, 5624 publications were analyzed, indicating an increasing trend in DME research. The United States was identified as the leading country in DME research, with the highest h-index of 135 and 91,841 citations. Francesco Bandello emerged as the most prolific author with 97 publications. Neil M. Bressler has the highest h-index and highest total citation count of 46 and 9692, respectively. The journals "Retina - the Journal of Retinal and Vitreous Diseases" and "Ophthalmology" were highlighted as the most prominent in this field. "Retina" leads with 354 publications, a citation count of 11,872, and an h-index of 59. Meanwhile, "Ophthalmology" stands out with the highest overall citation count of 31,558 and the highest h-index of 90. The primary research focal points in diabetic macular edema included "prevalence and risk factors," "pathological mechanisms," "imaging modalities," "treatment strategies," and "clinical trials." Emerging research areas encompassed "deep learning and artificial intelligence," "novel treatment modalities," and "biomarkers." CONCLUSION: Our bibliometric analysis delineates the leading role of the United States in DME research. We identified current research hotspots, including epidemiological studies, pathophysiological mechanisms, imaging advancements, and treatment innovations. Emerging trends, such as the integration of artificial intelligence and novel therapeutic approaches, highlight future directions. These insights underscore the importance of collaborative and interdisciplinary approaches in advancing DME research and clinical management.
Asunto(s)
Bibliometría , Retinopatía Diabética , Edema Macular , Edema Macular/epidemiología , Edema Macular/tratamiento farmacológico , Humanos , Investigación Biomédica/tendencias , Investigación Biomédica/estadística & datos numéricosRESUMEN
PURPOSE: We aimed to study the effects of aspirin intake for diabetic retinopathy (DR) and diabetic macular edema (DME) in a cohort from northeastern China. METHODS: Participants in the Fushun Diabetic Retinopathy Cohort Study were enrolled between July 2012 and May 2013. Fundus photographs of six fields were graded according to the modified Airlie House Classification system. The prevalence, incidence, progression, and regression of DR, as well as the prevalence/incidence of DME, were evaluated at baseline and during follow-up examinations after at least 1 year. RESULTS: In total, 1370 patients were enrolled in the study, and 270 (19.7%) were taking aspirin. The prevalence of any DR in participants with and without aspirin intake was 47.4% and 44.9%, respectively (P = 0.46). The incidence of any DR in patients with and without aspirin intake was 9.2% and 8.3%, respectively (P = 0.74). In univariate regression, there was no association between aspirin intake and the prevalence of any DR and DME (odds ratios (OR), 95% confidence intervals (CI): 0.93, 0.68-1.27 and 1.22, 0.79-1.88, respectively). Aspirin intake was not significantly associated with the prevalence and incidence of DME (OR, 95% CI: 1.22, 0.79-1.88 and 1.79, 0.62-5.17, respectively). Furthermore, aspirin intake was not significantly associated with DR progression or regression (OR, 95% CI: 1.04, 0.66-1.66 and 0.75, 0.52-1.09, respectively). CONCLUSION: Aspirin intake was not associated with the prevalence and incidence of any DR or DME in a northeastern Chinese population. Neither progression nor regression of DR revealed a significant association with aspirin intake.
Asunto(s)
Diabetes Mellitus Tipo 2 , Retinopatía Diabética , Edema Macular , Humanos , Factores de Riesgo , Diabetes Mellitus Tipo 2/complicaciones , Estudios de Cohortes , Retinopatía Diabética/complicaciones , Retinopatía Diabética/diagnóstico , Retinopatía Diabética/epidemiología , Edema Macular/diagnóstico , Edema Macular/epidemiología , Edema Macular/etiología , AspirinaRESUMEN
OBJECTIVE: To identify the risk factors for the development of diabetic retinopathy (DR), diabetic macular edema (DME), and sight-threatening DR (STDR) based on a city-wide diabetes screening program. RESEARCH DESIGN AND METHODS: Diabetic patients were prospectively recruited between June 2016 and December 2022. All patients underwent dilated fundus photography centered on the disc and macula or macular spectral domain optical coherence tomography (SD-OCT) scan. Complete medical history was documented. Systematic examination, blood analysis, and urinalysis were performed. Multivariate logistic regression analysis adjusting for age and sex was conducted. RESULTS: Out of 7274 diabetic patients, 6840 had gradable images, among which 3054 (42.0%) were graded as DR, 1153 (15.9%) as DME, and 1500 (20.6%) as STDR. The factors associated with DR, DME, and STDR included younger age (odds ratio [OR]: 0.96, 0.97, and 0.96 respectively), lower BMI (OR: 0.97, 0.95, and 0.95 respectively), longer duration of diabetes (OR: 1.07, 1.03, and 1.05 respectively) and positive of urinary albumin (OR: 2.22, 2.56, and 2.88 respectively). Other associated factors included elevated blood urea nitrogen (OR: 1.22, 1.28, and 1.27 respectively), higher LDL-cholesterol, lower blood hemoglobin (OR: 0.98, 0.98, and 0.98), insulin intake, presence of diabetic foot pathologies and diabetic peripheral neuropathy. We also identified novel risk factors, including high serum potassium (OR: 1.37, 1.46, and 1.55 respectively), high-serum sodium (OR: 1.02, 1.02, and 1.04 respectively). Better family income was a protective factor for DR, DME, and STDR. Alcohol consumption once a week was also identified as a protective factor for DR. CONCLUSIONS: Similar risk factors for DR, DME, and STDR were found in this study. Our data also indicates high serum sodium, high serum potassium, low blood hemoglobin, and level of family income as novel associated factors for DR, DME, and STDR, which can help with DR monitoring and management.
Asunto(s)
Retinopatía Diabética , Edema Macular , Tomografía de Coherencia Óptica , Humanos , Retinopatía Diabética/epidemiología , Retinopatía Diabética/diagnóstico , Masculino , Factores de Riesgo , Edema Macular/etiología , Edema Macular/epidemiología , Edema Macular/diagnóstico , Femenino , Persona de Mediana Edad , Estudios Prospectivos , Tomografía de Coherencia Óptica/métodos , Anciano , Agudeza Visual , Adulto , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/epidemiologíaRESUMEN
PURPOSE: To clarify the postoperative incidence of macular edema in patients undergoing surgery to repair rhegmatogenous retinal detachment and identify the associated risk factors. METHODS: In this prospective, observational study, 79 patients who underwent surgery to correct rhegmatogenous retinal detachment using pars plana vitrectomy with silicone oil injection were analyzed. Patients were followed up postoperatively at 7, 30, 90, 180, and 365 days. At each visit, optical coherence tomography was performed to assess the presence or absence of macular edema. were analyzed as possible risk factors for macular edema: age, sex, macular status (attached or detached), presence of vitreoretinal proliferation, history of previous intraocular surgery, reported time of symptoms suggestive of rhegmatogenous retinal detachment up to the date of surgery, and the surgical modality performed. RESULTS: The 1-year macular edema prevalence rate was 26.6%. In the adjusted analysis, older patients had a higher risk of macular edema, and each 1-year increase in age increased the risk of macular edema by 6% (95% confidence interval = 1.00-1.12). The macular status, vitreoretinal proliferation, the surgical technique used, prior intraocular surgery, and the intraocular lens status were not identified as risk factors. However, the incidence of macular edema increased up to 180 days after surgery, peaking at 10.6%, and then decreased until 365 days after surgery. CONCLUSION: Macular edema was a common complication after surgery to treat rhegmatogenous retinal detachment, with its incidence peaking between 30 and 180 days after surgery. Age was an important risk factor for macular edema in this cohort.
Asunto(s)
Edema Macular , Desprendimiento de Retina , Tomografía de Coherencia Óptica , Vitrectomía , Humanos , Desprendimiento de Retina/cirugía , Desprendimiento de Retina/etiología , Masculino , Femenino , Edema Macular/etiología , Edema Macular/epidemiología , Persona de Mediana Edad , Factores de Riesgo , Estudios Prospectivos , Vitrectomía/efectos adversos , Vitrectomía/métodos , Incidencia , Adulto , Estudios de Seguimiento , Tomografía de Coherencia Óptica/métodos , Anciano , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/etiología , Agudeza Visual , Aceites de Silicona/efectos adversos , Aceites de Silicona/administración & dosificación , Factores de Tiempo , Factores de Edad , Adulto JovenRESUMEN
PURPOSE: The worldwide prevalence of diabetes mellitus (DM) continues to increase. As DM is linked to various ophthalmological comorbidities, it is crucial to understand the incidence and the treatment patterns of these complications to minimise the treatment burden for the patient and the healthcare system. This study aims to evaluate the incidence and prevalence of diabetic macular oedema (DME) and proliferative diabetic retinopathy (PDR) and to analyse intravitreal (IVT) treatment patterns and responses in the Finnish population with diabetes. METHODS: A nationwide data register containing details of over 20-year-old individuals with diabetes was used in the analyses. RESULTS: The incidence and prevalence of DME and PDR among the Finnish population with diabetes either declined or remained stable during 2007-2017 (Incidence rate: DME -40.8%, PDR -65.3%; prevalence rate: DME +4.7%, PDR -11.2%). During the same period, number of persons suffering from diabetes increased by +58.3%. The total number of IVT injections increased by 261.7%; the number of patients receiving IVT treatments increased by 133.6% from 2011 to 2017, reflecting changes in patient numbers in the ophthalmology departments. Furthermore, irrespective of the rising number of patients with diabetes, the numbers with visual impairment declined by 75.8% among DME and by 75.7% among PDR patients in 2007-2017. CONCLUSIONS: Regardless of the considerable increase in the workload of ophthalmology departments, the healthcare system has been able to reduce both the age and sex standardised incidence of DME and PDR among the diabetic population suffering from a visual impairment associated with this disease.
Asunto(s)
Inhibidores de la Angiogénesis , Retinopatía Diabética , Progresión de la Enfermedad , Inyecciones Intravítreas , Edema Macular , Agudeza Visual , Humanos , Retinopatía Diabética/epidemiología , Retinopatía Diabética/tratamiento farmacológico , Retinopatía Diabética/complicaciones , Retinopatía Diabética/diagnóstico , Edema Macular/epidemiología , Edema Macular/tratamiento farmacológico , Edema Macular/etiología , Incidencia , Finlandia/epidemiología , Masculino , Femenino , Prevalencia , Persona de Mediana Edad , Inhibidores de la Angiogénesis/administración & dosificación , Anciano , Adulto , Sistema de Registros , Adulto Joven , Estudios Retrospectivos , Estudios de Seguimiento , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidoresRESUMEN
AIMS: There are limited studies on dipeptidyl-peptidase 4 inhibitor (DPP-4i), sodium glucose cotransporter 2 inhibitor (SGLT2-i), and glucagon-like peptide 1 (GLP-1) receptor agonist use and occurrence of diabetic macular edema (DME). The objective of this study was to determine the association between DPP-4i, SGLT2-i, and GLP-1 receptor agonist use and occurrence of DME. METHODS: Proportional hazard models were used to evaluate the change in hazard of developing DME associated with DPP-4i, SGLT2-i, or GLP-1 receptor agonist use. Models accounted for age at DR diagnosis, DR severity (proliferative vs non-proliferative stage), time-weighted average of HbA1c level, sex, and self-reported race/ethnicity. A p-value ≤ 0.05 was considered statistically significant. RESULTS: The hazard ratio of developing DME after diagnosis of DR was 1.2 (CI = 0.75 to 1.99; p = 0.43) for DPP-4i use, 0.93 (CI = 0.54 to 1.61; p = 0.81) for GLP-1 receptor agonist use, 0.82 (CI = 0.20 to 3.34; p = 0.78) for SGLT2-i use, 1.1 (CI = 0.75 to 1.59; p = 0.66) for any one medication use, 1.1 (CI = 0.62 to 2.09; p = 0.68) and for any two or more medications use. CONCLUSIONS: We did not find an association between DPP-4i, SGLT2-i, or GLP-1 receptor agonist use and increased hazard of development of DME among patients with DR.
Asunto(s)
Diabetes Mellitus Tipo 2 , Retinopatía Diabética , Inhibidores de la Dipeptidil-Peptidasa IV , Receptor del Péptido 1 Similar al Glucagón , Edema Macular , Inhibidores del Cotransportador de Sodio-Glucosa 2 , Humanos , Retinopatía Diabética/epidemiología , Inhibidores del Cotransportador de Sodio-Glucosa 2/uso terapéutico , Inhibidores del Cotransportador de Sodio-Glucosa 2/efectos adversos , Inhibidores de la Dipeptidil-Peptidasa IV/uso terapéutico , Inhibidores de la Dipeptidil-Peptidasa IV/efectos adversos , Masculino , Femenino , Receptor del Péptido 1 Similar al Glucagón/agonistas , Persona de Mediana Edad , Anciano , Edema Macular/epidemiología , Edema Macular/inducido químicamente , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/complicaciones , Hipoglucemiantes/uso terapéutico , Hipoglucemiantes/efectos adversos , Estudios de CohortesRESUMEN
PURPOSE: To characterize the incidence of kidney failure associated with intravitreal anti-VEGF exposure; and compare the risk of kidney failure in patients treated with ranibizumab, aflibercept, or bevacizumab. DESIGN: Retrospective cohort study across 12 databases in the Observational Health Data Sciences and Informatics (OHDSI) network. SUBJECTS: Subjects aged ≥ 18 years with ≥ 3 monthly intravitreal anti-VEGF medications for a blinding disease (diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, or retinal vein occlusion). METHODS: The standardized incidence proportions and rates of kidney failure while on treatment with anti-VEGF were calculated. For each comparison (e.g., aflibercept versus ranibizumab), patients from each group were matched 1:1 using propensity scores. Cox proportional hazards models were used to estimate the risk of kidney failure while on treatment. A random effects meta-analysis was performed to combine each database's hazard ratio (HR) estimate into a single network-wide estimate. MAIN OUTCOME MEASURES: Incidence of kidney failure while on anti-VEGF treatment, and time from cohort entry to kidney failure. RESULTS: Of the 6.1 million patients with blinding diseases, 37 189 who received ranibizumab, 39 447 aflibercept, and 163 611 bevacizumab were included; the total treatment exposure time was 161 724 person-years. The average standardized incidence proportion of kidney failure was 678 per 100 000 persons (range, 0-2389), and incidence rate 742 per 100 000 person-years (range, 0-2661). The meta-analysis HR of kidney failure comparing aflibercept with ranibizumab was 1.01 (95% confidence interval [CI], 0.70-1.47; P = 0.45), ranibizumab with bevacizumab 0.95 (95% CI, 0.68-1.32; P = 0.62), and aflibercept with bevacizumab 0.95 (95% CI, 0.65-1.39; P = 0.60). CONCLUSIONS: There was no substantially different relative risk of kidney failure between those who received ranibizumab, bevacizumab, or aflibercept. Practicing ophthalmologists and nephrologists should be aware of the risk of kidney failure among patients receiving intravitreal anti-VEGF medications and that there is little empirical evidence to preferentially choose among the specific intravitreal anti-VEGF agents. FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Asunto(s)
Inhibidores de la Angiogénesis , Bevacizumab , Inyecciones Intravítreas , Ranibizumab , Receptores de Factores de Crecimiento Endotelial Vascular , Proteínas Recombinantes de Fusión , Insuficiencia Renal , Factor A de Crecimiento Endotelial Vascular , Humanos , Receptores de Factores de Crecimiento Endotelial Vascular/administración & dosificación , Proteínas Recombinantes de Fusión/administración & dosificación , Proteínas Recombinantes de Fusión/efectos adversos , Ranibizumab/administración & dosificación , Ranibizumab/efectos adversos , Bevacizumab/administración & dosificación , Bevacizumab/efectos adversos , Inhibidores de la Angiogénesis/administración & dosificación , Inhibidores de la Angiogénesis/efectos adversos , Estudios Retrospectivos , Masculino , Femenino , Insuficiencia Renal/epidemiología , Insuficiencia Renal/complicaciones , Insuficiencia Renal/inducido químicamente , Incidencia , Anciano , Persona de Mediana Edad , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Retinopatía Diabética/tratamiento farmacológico , Retinopatía Diabética/epidemiología , Retinopatía Diabética/diagnóstico , Retinopatía Diabética/complicaciones , Estudios de Seguimiento , Factores de Riesgo , Edema Macular/tratamiento farmacológico , Edema Macular/epidemiología , Edema Macular/diagnóstico , Oclusión de la Vena Retiniana/tratamiento farmacológico , Oclusión de la Vena Retiniana/diagnóstico , Oclusión de la Vena Retiniana/complicaciones , Oclusión de la Vena Retiniana/epidemiología , Ceguera/epidemiología , Ceguera/inducido químicamente , Ceguera/prevención & control , Ceguera/diagnóstico , Ceguera/etiologíaAsunto(s)
Diabetes Mellitus , Retinopatía Diabética , Edema Macular , Humanos , Edema Macular/epidemiología , Edema Macular/etiología , Incidencia , Finlandia/epidemiología , Retinopatía Diabética/epidemiología , Retinopatía Diabética/complicaciones , Estudios Epidemiológicos , Tomografía de Coherencia ÓpticaRESUMEN
Objetivo: Evaluar la efectividad del tratamiento combinado con dorzolamida tópica en pacientes con edema quístico macular poscirugía de catarata. Métodos: Se realizó un estudio experimental en pacientes atendidos en el Servicio de Vítreo-Retina del Instituto Cubano de Oftalmología "Ramón Pando Ferrer", en el año 2018. Se definió el grupo de casos (dorzolamida y tratamiento convencional) y el grupo control (tratamiento convencional), los cuales se evaluaron en la consulta inicial y al mes de tratamiento. Resultados: La edad media fue de 60,73 ± 11,25 años. Predominó el sexo femenino (53,33 por ciento), el ojo afectado derecho (60,00 por ciento), el tiempo posquirúrgico ≤ 3 meses (63,33 por ciento), sin factores de riesgo asociados (56,67 por ciento). El edema sin alteraciones asociadas fue más frecuente (80,00 por ciento). La media del grosor macular disminuyó en ambos grupos (de 529,27 ± 183,58 a 349,93 ± 221,35 en los casos y de 498,87 ± 213,26 a 373,53 ± 215,51 en los controles). Resultó mayor la variación en el grupo de casos (179,33 p= 0,008). La agudeza visual aumentó en ambos grupos. Se observó un porcentaje mayor de ojos que mejoraron la visión en el grupo de casos (52,38 por ciento). La mejoría de la agudeza visual se relacionó con la recuperación del grosor macular. Conclusiones: En los casos con edema quístico macular poscirugía de catarata, en los que está indicado el tratamiento tópico con antinflamatorios, la combinación con dorzolamida resulta efectiva para la reducción del grosor macular y la mejoría de la agudeza visual corregida(AU)
ABSTRACT Objective: Evaluate the effectiveness of a treatment combined with topical dorzolamide in patients with cystoid macular edema after cataract surgery. Methods: An experimental study was conducted of patients attending the Vitreous-Retina Service at Ramón Pando Ferrer Cuban Institute of Ophthalmology in the year 2018. The sample was divided into a case group (dorzolamide and conventional treatment) and a control group (conventional treatment), and evaluated at the initial consultation and after one month of treatment. Results: Mean age was 60.73 ± 11.25 years. A predominance was found of the female sex (53.33 percent), affected right eye (60.00 percent), postsurgical time ≤ 3 months (63.33 percent), and no associated risk factors (56.67 percent). Edema without associated alterations was more common (80.00 percent). Mean macular thickness decreased in both groups (from 529.27 ± 183.58 to 349.93 ± 221.35 in cases and from 498.87 ± 213.26 to 373.53 ± 215.51 in controls). Variation was greater in the case group (179.33 p= 0.008). Visual acuity increased in both groups. A higher percentage of eyes with improved vision was found in the case group (52.38 percent). Visual acuity improvement was related to macular thickness recovery. Conclusions: In cases of cystoid macular edema after cataract surgery with indication of topical treatment with anti-inflammatories, the combination with dorzolamide is effective to reduce macular thickness and improve corrected visual acuity(AU)
Asunto(s)
Humanos , Extracción de Catarata/métodos , Edema Macular/epidemiología , Antiinflamatorios/uso terapéutico , Resultado del TratamientoRESUMEN
INTRODUCTION: The incidence of cystoid macular edema (CME) after cataract surgery varies substantially and depending on the diagnostic method used. In addition, other factors that influence the incidence of CME are the technique of surgery and the associated comorbidities. OBJECTIVE: The aim of the present study was to evaluate the incidence of EMC after uncomplicated phacoemulsification surgery, using the spectral domain optical coherence tomography (OCT). METHODS: The incidence of subclinical and clinical CME was evaluated in 14 patients who underwent uncomplicated phacoemulsification surgery, using OCT before the surgical procedure and after seven and 28 days after it. The volunteers could not use a prostaglandin analogue or present any retinopathy that compromised visual acuity. RESULTS: The incidence of clinically significant CME was 6.4%, however retinal thickening by OCT was observed in all patients in the fourth postoperative week. Regarding gender and laterality, the percentages were similar. CONCLUSION: In this study, we obtained a low incidence of EMC in patients assisted at this center, corroborating multicenter studies.
Asunto(s)
Humanos , Masculino , Femenino , Periodo Posoperatorio , Catarata , Edema Macular/epidemiología , Edema Macular/diagnóstico por imagen , Facoemulsificación , Tomografía de Coherencia Óptica , Agudeza Visual , Servicios de Salud OcularRESUMEN
INTRODUCCIÓN: La Retinopatía Diabética (RD) es una complicación microangiopática de la diabetes y una de las principales causas de ceguera a nivel mundial. La principal complicación de la RD es el edema macular diabético (EMD). El objetivo de este trabajo es determinar la prevalencia de RD y sus subtipos, así como de EMD en una población de pacientes diabéticos de la atención primaria (APS) de Antofagasta. MATERIALES Y MÉTODOS: Estudio descriptivo de corte transversal realizado en una población de 380 pacientes diabéticos diagnosticados y tratados en siete centros de APS de Antofagasta sometidos a control anual de tamizaje de RD mediante retinografía. Se analizó sexo, edad, presencia de RD y subtipos y EMD. RESULTADOS: Se encontró prevalencia de RD de 19.21%. Dentro de este grupo la mayoría (60.27%) fueron hombres y el rango de edad predominante fue 40-64 años con 60.27%. El subtipo más frecuente fue la RD no proliferativa moderada con 45.21% y la prevalencia de EMD fue de 1.84%. CONCLUSIONES: La RD es una complicación prevalente y prevenible, por lo que es necesario mejorar los programas de control metabólico y métodos de screening. Este estudio aporta nuevos datos a la escasa literatura nacional sobre el tema.
INTRODUCTION: Diabetic retinopathy (DR) is a diabetic microangiopatic complication and the leading cause of blindness worldwide. The principal complication of DR is diabetic macular edema (DME). The objective of this study is to determine the prevalence of DR and their subtypes, as well as DME in a primary health care (PC) diabetic population of Antofagasta. ;ATERIAL AND METHODS: This is a transversal descriptive study carried out in a population of 380 diabetic patients diagnosed and treated in Antofagasta's seven PC centers, who underwent an anual retinography for DR screening. The factors analyzed were sex, age, presence of RD and their subtypes, and DME. RESULTS: We found a RD prevalence of 19.21%. In this group, the majority were men and the age group of 40-64 years showed the highest prevalence. The more frequent subtype (45.21%) was moderate non-proliferative DR, and the prevalence of DME was 1.84%. CONCLUSIONS: RD is a prevalent and preventable complication, and metabolic control programs and screening methods must be improved. This study contributes new data to the scarse national literature of this topic.
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Atención Primaria de Salud , Edema Macular/epidemiología , Retinopatía Diabética/epidemiología , Chile , Tamizaje Masivo , Epidemiología Descriptiva , Prevalencia , Estudios Transversales , Técnicas de Diagnóstico Oftalmológico , Distribución por Edad y Sexo , Fondo de OjoRESUMEN
Objective: To evaluate the impact of a strategy for early detection of diabetic retinopathy in patients with type 2 diabetes mellitus (DMT2) in Quintana Roo, México. Methods: Study transversal, observational, prospective, analytical, eight primary care units from Mexican Social Security Institute in the northern delegation of the State of Quintana Roo, Mexico were included. A program for early detection of diabetic retinopathy (DR) in adult 376,169 was designed. Were diagnosed 683 cases of type 2 diabetes, in 105 patients randomized was conducted to direct ophthalmoscopy were subjected to a secondary hospital were assigned. Will determine the degree of diabetic retinopathy and macular edema was performed. Results: In population were 55.2% female, mean age 48+11.1 years, 23.8 % had some degree of DR, 28.0% with mild non- proliferative diabetic retinopathy 48.0 % moderate 16.0% and severe and 8.0% showed proliferative diabetic retinopathy. Those over age 30 are 2.8 times more risk of developing DR, OR= 2.8; 95%CI: 0.42-18.0, and OR= 1.7; 95%CI: 1.02-2.95 women. Conclusions: The implementation of programs aimed at the early detection of debilitating conditions such as diabetic retinopathy health impact beneficiaries, effective links between primary care systems and provide second level positive health outcomes for patient diseases.
Objetivo: Evaluar el impacto de una estrategia para la detección temprana de Retinopatía Diabética en pacientes con Diabetes Mellitus tipo 2 (DM2) en Quintana Roo. Métodos: Estudio Transversal, observacional, prospectivo, analítico. En Ocho unidades de primer nivel de atención de la delegación Norte del Estado de Quintana Roo, México del Instituto Mexicano del Seguro Social. Se diseñó un programa de detección oportuna de retinopatía diabética en 376,169 adultos, se realizó el diagnóstico de 683 casos de DM2, de forma aleatoria se asignaron 105 pacientes a quienes se les practicó oftalmoscopia directa en un hospital de segundo nivel. Se realizó la determinación del grado de retinopatía diabética y edema macular. Resultados: En la muestra predominaron las mujeres: 55.2%, edad promedio de 48+11.1 años, el 23.8% presentó algún grado de DR, 28.0% con retinopatía diabética no proliferativa leve (DRnPL), 48.0% moderada (DRnPM), 16.0% Severa (DRnPS) y el 8.0% presento Retinopatía diabética proliferativa (DRP). Los mayores de 30 años tuvieron 2.8 veces más riesgo de desarrollar DR, OR 2.8; IC95%: 0.42-18.0 al igual que las mujeres OR= 1.7; IC95%: 1.02-2.95. Conclusiones: La realización de programas dirigidos a la detección oportuna de enfermedades incapacitantes como la retinopatía diabética tienen impacto en la salud de los derechohabientes, la vinculación efectiva entre los sistemas de atención primaria y segundo nivel ofrecen resultados favorables para la salud de los pacientes.
Asunto(s)
Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , /complicaciones , Retinopatía Diabética/diagnóstico , Edema Macular/diagnóstico , Factores de Edad , Estudios Transversales , Retinopatía Diabética/epidemiología , Retinopatía Diabética/patología , Diagnóstico Precoz , Edema Macular/epidemiología , Edema Macular/etiología , México/epidemiología , Oftalmoscopía , Estudios Prospectivos , Atención Primaria de Salud/métodos , Índice de Severidad de la EnfermedadRESUMEN
Introducción: La retinopatía diabética (RD) es una microangiopatía progresiva a nivel retinal que aparece como complicación de la diabetes y es una delas principales causas de ceguera en el mundo. En los diabéticos la principal causa de pérdida visual es el edema macular diabético (EMD). Presentamos un trabajo cuyo objetivo es describir la prevalencia de RD y subtipos y EMD en una población de pacientes diabéticos en un centro de atención primaria del país. Materiales y métodos: Estudio transversal descriptivo realizado en un grupo de 468 pacientes diabéticos del CESFAM Cordillera Andina de Los Andes, sometidos a examen anual de fondo de ojo. Los parámetros analizados en este estudio fueron: sexo, edad, años de diagnóstico de diabetes mellitus(DM), presencia de RD y subtipos y EMD. Resultados: Se encontró una prevalencia de RD de 24,78 por ciento. El grupo etario entre los 50-70 años presentó la mayor prevalencia de RD mientras que el 51,7 por ciento de pacientes con RD tenía 10 o más años de diagnóstico de DM2. El subtipo más frecuente fue la RD no proliferativa (RDNP) leve(37,1 por ciento). La prevalencia de EMD fue 3,8 por ciento. Conclusiones: Se aportan nuevos datos a la escasa literatura nacional disponible, destacando la medición de prevalencia de EMD.
Introduction: Diabetic retinopathy (DR) is a progressive microangiopathy at the retinal level which appears as a complication of diabetes and is a major cause of blindness in the world. In diabetics, the leading cause of visual loss is diabetic macular edema (DME). We present a study which aims to determine the prevalence of DR and subtypes and DME in a population of diabetic patients in a primary care center of the country. Materials and Methods: Transversal descriptive study carried out in a group of 468 diabetic patients of Cordillera Andina from Los Andes Family Health Center (CESFAM), who underwent an annual fundoscopy. The factors analyzed in this study were: sex, age, years of diagnosis of diabetes, presence of DR and subtypes and DME. Results: We found a prevalence of DR of 24.78 percent. The most frequent subtype was mild non-proliferative diabetic retinopathy (NPDR) (37.1 percent). The age group between 50-70 years old showed the biggest prevalence, while 51.7 percent of patients with DR had ten or more years of diagnosis of diabetes. DME prevalence was 3.8 percent. Conclusions: This study provides new data to add to the limited available national literature, highlighting the prevalence of DME measurement.
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Atención Primaria de Salud/estadística & datos numéricos , Edema Macular/epidemiología , Salud de la Familia , Retinopatía Diabética/epidemiología , Distribución por Edad , Factores de Edad , Chile , Estudios Transversales , Complicaciones de la Diabetes/epidemiología , Epidemiología Descriptiva , Tamizaje Masivo , PrevalenciaRESUMEN
El edema macular, provocado por múltiples causas, constituye un problema importante de salud ocular. Se realizó la presente investigación en 96 ojos de 150 pacientes que acudieron al Servicio de Retina del Hospital Dr Salvador Allende entre enero y diciembre de 2008. Se incluyeron todos los casos con diagnóstico confirmado de edema macular difuso que quisieron participar en la investigación, a los que se les realizó examen bajo midriasis con oftalmoscopía indirecta, biomicroscopía en lámpara de hendidura con lente aéreo de 90 dioptrías, angiografía fluoresceínica y la tomografía óptica coherente. Se determinó la prevalencia del edema macular y su comportamiento socio-demográfico y clínico-epidemiológico. Se identificaron los factores de riesgo y las causas más frecuentes que lo originaron. Se concluyó que el edema macular predominó en el sexo femenino y en pacientes de 61 años en adelante. Los principales factores de riesgo identificados fueron la diabetes mellitus y las cirugías oculares previas. El edema macular diabético fue la causa vascular más frecuente. Entre las inflamatorias, las secundarias a cirugía de catarata y entre las distrofias, la retinosis pigmentaria.
Macular Edema, caused by multiple causes, is an important eye health problem. This research was performed in 96 eyes of 150 patients that came to the Retina Service at Dr Salvador Allende Hospital, between January and December 2008. It was included all cases with confirmed diagnosis of diffuse macular edema who wanted to participate in the investigation, to those that carried out under mydriasis using indirect ophthalmoscope, biomicroscopy in slit-lamp with air lens of 90 diopters, fluorescein angiography and optical coherence tomography. The prevalence of macular edema and its socio-demographic and clinical epidemiology behavior was determined. It was identified risk factors and common causes that originated it. It was concluded that macular edema was predominant in females and in patients aged 61 and older. The main risk factors identified were diabetes mellitus and previous ocular surgeries. Diabetic macular edema was the most common vascular cause. Among the inflammatory, secondary to cataract surgery and between dystrophy, retinitis pigmentosa.